Accelerate your therapeutic antibody programs, from early concept to IND submission, with Pharmaron’s fully integrated discovery and development services. The platform supports monoclonal, bi-specific, multi-specific, research, and diagnostic antibodies, offering a seamless path through every stage of development.
Discover novel candidates using Pharmaron’s phage display and hybridoma platforms. Its team brings deep expertise in antibody humanization, affinity maturation, and Fc engineering to generate potent molecules with reduced immunogenicity risk.
Choose from transient or stable expression options, including high-throughput workflows, followed by detailed characterization using advanced biophysical methods, mass spectrometry, and structural biology.
Access over 4000 validated assays and a broad range of disease models to evaluate the mode of action and biological activity. Integrated bioanalysis supports robust PK/PD profiling.
From antibody production (non-GMP and GMP) to pharmacology, GLP toxicology, and regulatory support, Pharmaron’s team works to get you from lead candidate to IND submission in as little as 12 months.
Download your copy of the eBook now to explore case studies and see how Pharmaron’s therapeutic antibody discovery and development services can help move your program forward.
About Pharmaron
Pharmaron is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.